Have £4k to invest in your ISA? 2 dividend growth stocks I’d buy and hold ‘til 2030

Are you seeking to generate chunky income flows from your Stocks & Shares ISA? Of course you are. And these dividend stars could be just what you’re looking for, says Royston Wild.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Alliance Pharma (LSE: APH) might not be a name that immediately comes to mind when you think of dividend-paying pharma stocks. But for all serious income investors, it’s a share that’s worth buying because of its exceptional profits outlook for the next decade.

What makes the AIM-quoted company such a great dividend share is the rate at which it’s consistently raises annual dividends. Last year, it hiked the total payout 10% to 1.46p per share and City analysts expect Alliance to increase them by the same percentage in both 2019 and 2020, resulting in projections of 1.6p and 1.76p for these respective years.

A medical miracle

Sure, there’s bigger yields out there than the 2% and 2.5% for this year and next, though I’d argue that Alliance’s bright profits outlook — and thus the prospect for more strong and sustained dividend growth thereafter — still makes it worth a serious look.

Latest financials showed revenues boomed 28% (at constant exchange rates) between January and June owing to soaring demand for its ‘International Star’ labels such as Kelo-cote and Nizoral. Sales of these products rocketed 79% in the first half, or 21% on a like-for-like basis.

What’s more, the huge steps Alliance has made in developing its business in the growth markets of Asia Pacific gives investors a lot to get excited about too. Sales here of the flagship Kelo-cote scar treatment for instance soared by 20% in the six months to June.

Short-term pain, long-term gain

I’d argue that Britvic (LSE: BVIC) is another solid dividend growth pick to hold through to 2030, and possibly beyond. It’s certainly true the soft drinks manufacturer — owner of beloved labels including Robinsons, R Whites and Lipton — hasn’t had things all its own way recently, due to difficult trading conditions in Ireland and France. These woes caused group revenues to fall 1.5% at constant currencies in the three months to July 7.

Largely speaking though, the immense brand power of Britvic’s products remains undimmed and, even though it’s not immune to sales lumpiness now and again, the enduring appeal of its drinks provides the sort of long-term earnings visibility that enables the company to raise dividends year after year.

Brand brilliance

Besides, Britvic’s dedication to innovation can be relied upon to keep its brands fresh and flying off the shelves, allowing it to also ride the rising popularity of low calorie drinks. Some of its more successful rollouts in recent times include Pepsi Max Cherry, 7UP Free and a range of its Robinsons juices. I’d argue the FTSE 250 firm has taken on the challenge of the UK sugar tax and used it to create an advantage over its rivals.

One final thing. Amid City expectations of further profits growth in the year to September 2020, an upgraded 31.5p per share dividend is expected, one that yields an inflation-beating 2.9%. I’d happily add Britvic and Alliance Pharma to my income-generating ISA today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Britvic. The Motley Fool UK has recommended Alliance Pharma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »